glp 1 patent expiration Ozempic, Wegovy and Rybelsus: The patents behind Novo Nordisk's weight-loss drugs Ozempic's Patent Protection Starts to

So when someone says, GLP-1s cause muscle loss, the first question should be: what exactly was measured

However, more studies are needed.

We break down the key differences in mechanism, evidence base, side effects, and who each one is actually relevant for.

Major kudos to Chad Janis and the entire Grns team

PlexusDx explores the clinical evidence, safety considerations, and personalized alternatives for patients seeking advanced metabolic support

In our newly released white paper, From Managing Illness to Building Health, we outline why fragmented, condition-specific approaches are no longer aligned with clinical science or financial outcomes and what a more integrated, prevention-focused model looks like in practice